Bookmark and Share

Steven J Feigenberg
View Curriculum Vitae 

Steven J Feigenberg M.D.

Academic Title: Professor
Primary Appointment: Radiation Oncology
Administrative Title: Director For Clinical Research
Additional Title(s): Director of Stereotactic Body Radiotherapy Program / Director of Emerging Technologies, Dept. of Radiation Oncology
sfeigenberg@umm.edu
Location: UMMC, GGK19
Phone: (410) 328-2328
Fax: (410) 328-6911

Personal History:

Dr. Feigenberg is currently a Professor in the Department of Radiation Oncology at the University of Maryland School of Medicine. He received his B.S. in Chemical Engineering from Drexel University in 1991. He received his medical degree from Hahnemann University School of Medicine in 1997. He completed an internship in Internal Medicine at Temple University Hospital in Philadelphia and residency in Radiation Oncology at the University of Florida in Gainesville, where he developed his research interest in breast cancer and stereotactic radiotherapy and radiosurgery. Since completing his training in 2002, he worked at Fox Chase Cancer Center in Philadelphia where his clinical and research interests focused on lung cancer, head & neck cancer with a special interest in stereotactic radiotherapy. Soon after his arrival at Fox Chase Cancer, he started and developed their Stereotactic Radiosurgery and Stereotactic Body Radiotherapy Program.

In 2009, he was recruited by University of Maryland’s Department of Radiation Oncology as the Director of Clinical Research and Director of Stereotactic Body Radiotherapy Program with one his main goals to lead the clinical implementation of the 1st breast specific radiotherapy device, the GammaPod™.

Research Interests:

Dr. Feigenberg’s current interest continues to be centered around stereotactic radiotherapy and developing non-invasive methods to predict treatment responses. This is of utmost importance now that we are comparing this approach to surgery. Trying to develop early surrogates of treatment response are imperative to allow early surgical salvage if/when necessary. We are also investigating the mechanism of this novel technique which appears to be related to stimulating the immune system causing one’s body to fight tumor cells.


Publications:

Selected Recent Publications

Feigenberg SJ, Mendenhall NP, Reith JD, Ward JR, Copeland EM, III.  Angiosarcoma after breast-conserving therapy:  experience with hyperfractionated radiotherapy.  Int J Radiat Oncology Biol Physics, 2002 Mar 1;52(3): 620-626.

Feigenberg SJ, Monroe AT, Mendenhall NP.  Angiosarcoma after breast-conserving therapy.  Cancer. 2003 Apr  15;97(8) 1832-40

Ward JR, Feigenberg SJ, Mendenhall NP, Marcus RB, Jr., Mendenhall WM.  Radiation Therapy for Angiosarcoma.  Head & Neck 2003, Apr 24(4): 384-9.
 
Feigenberg SJ, Mendenhall N, Benda RK, Morris CG.  Postmastectomy radiotherapy:  Patterns of Recurrence and long-term disease control using electrons.  Int J Radiat Oncol Biol Phys, 2003 Jul 1;56(3): 716-25.

Konski A, Feigenberg SJ, Chow E.  Palliative Radiation Therapy.  Semin Oncol, 2005 Apr; 32(2): 156-64

Ettinger DS, Bepler G, Bueno R, Change A, Chang JY, Chirieac LR, D’A,ocp TA, Demmy TL, Feigenberg SJ, Grannis FW, Jr., Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE; National Comprehensive Cancer Network (NCCN).  Non-small cell lung cancer clinical practice guidelines in oncology.  J Natl Compr Canc Netw, 2006 Jul; 4(6): 548-82.

Feigenberg SJ, Hanlon AL, Langer C, Goldberg M, Nicolaou N, Millenson M, Coia LR, Lanciano R, Movsas B.  A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA non-small cell lung cancer.  J Thoracic Oncol, 2007 Mar; 2(3): 203-9.

Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, Copeland EM, III, Mendenhall NP.  Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy:  the importance of radiation field selection.  Int J Radiat Oncol Biol Phys, 2007 Mar 15; 67(4): 1043-51

Scott WJ, Howington J, Feigenberg SJ, Movasas B, Pisters K; American College of Chest Physicians.  Treatment of non-small cell lung cancer stage 1 and stage II:  ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007 Sept 132(3 Suppl): 234S-242S.

Jin L, Wang L, Li J, LW, Feigenberg SJ, Ma C-M.  Investigation of optimal beam margins for stereotactic radiotherapy of lung-cancer using Monte Carlo dose calculations.  Phys Med Biol, 2007 52; 3549-3561.

Wang L, Hayes S, Paskalev K, Jin L, Buyyounouski M, Ma M, Feigenberg SJ.  Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer:  Evaluation of the impact on daily dose coverage.  Radiotherapy and Oncology, 2008 Jun 91(3): 314-24.  Epub  2008 Dec 26.

Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE.  Multi-institutional Phase I/II Trial of Stereotactic Body Radiation therapy for Liver Metastases.  J Clin Oncol, 2009 Apr 1;27(10): 1572-10.

Cohen RJ, Sharma NK, Yu JQ, Wang L, Buyyounouski MK, Unger M, Borghei H, King E, Scott W, Callahan E, Movsas BJ, Feigenberg SJ.  A Phase I Radiation dose escalation of stereotactic body radiotherapy for malignant lung tumors.  JBiSE,  2010 Apr 3(4); 351-358.

Movsas B, Langer CJ, Ross HK, Wang L, Jotte RM, Feigenberg SJ, Xu F, Huang CH, Monberg MJ, Obasaju CK.  Randomized Phase II Trial of Cisplatin, Etoposide and Radiation followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B unresected Non-small Cell Lung Cancer.  J Thorac Oncol, May 2010 5(5); 673-679.

Husain ZA, Mahmood U, Hanlon A, Neuner G, Buras R, Tkaczuk K, Feigenberg SJ.  Accelerated Partial Breast Irradiation via Brachytherapy:  A patterns-of-care analysis with ASTRO consensus statement groupings.  Brachytherapy, 2011 Jun [Epub ahead of print].

Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, Chumsri S, Bao T, Tkaczuk K, Feigenberg SJ.  Similar survival with breast conservation therapy or mastectomy in the management of your women with early-stage breast cancer.  Int J Radiat Oncol Biol Phys, 2012 Aug 1;83(5): 1387-93.

Wang L, Feigenberg SJ, Fan J, Jin L, Turaka A, Chen L, Ma CM.  Target repositional accuracy and PTV margin verification using three-dimensional cone-beam computed tomography (CBCT) in stereotactic body radiotherapy (SBRT) of lung cancers.  J Appl Clin Med Phys, 2012 Mar 8;13(2): 3708.

Feigenberg SJ, Campassi C, Sharma N, Yu JQ, Kesmodel SB, Patel R, Tkaczuk K.  Integration of Modern Imaging into the Multidisciplinary Setting:  The Radiation Oncology Perspective.  Applied Radiation Oncology, 2012 Oct.

Awan A, Cohen RJ, Campassi C, Kesmodel SB, Bellavance E, Tkaczuk K, Feigenberg SJ.  MRI and its impact on partial breast irradiation.  Applied Radiation Oncology, 2012 Oct

Reese A, Feigenberg SJ, Husain Z, Webb T, Hausner P, Edelman M, Feliciano J, Tkaczuk K, Sharma, N.  Stereotactic Ablative Radiotherapy (SABR):  Impact on the Immune System and Potential for Future Therapeutic Modulation.  Molecular and Cellular Pharmacology special issue on “New Insights in the cellular and molecular response to Radiation Therapy, 2012.

Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg SJ, D’Souza W, Suntharalingam M, Lu W.  Spatial-Temporal FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.  Int J Radiat Oncol Biol Phys, 2013 Apr 1;85(5): 1375-82 [Epub 2012 Dec 6].

Nichols EM, Feigenberg SJ, Marter K, Cheston SB, Lasio G, Tkaczuk K, Kesmodel S, Buras R, Regine WF.  Pre-operative Radiation Therapy Significantly Increases Patient Eligibility for Accelerated Partial Breast Irradiation using  3-D Conformal Radiotherapy.  Am J Clin Oncol, 2013 Jun; 36(3): 232-8.

Mahmood U, Hanlon Al, Koshy M, Buras R, Chumsri S, Tkaczuk K, Cheston SB, Regine WF, Feigenberg SJ.  Increasing National Mastectomy Rates for the Treatment of Early Stage Breast Cancer.  Ann Surg Oncol, 2013 May; 20(5): 1436-43.

Mistry NN, Diwanji T, Shi X, Pokharel S, Feigenberg SJ, Scharf SM, D’Souza WD.  Evaluation of fractional regional ventilation using  4D-CTand effects of breathing maneuvers on ventilation.  Int J Radiat Oncol Biol Phys, 2013 Nov 15;87(4):825-31.

Ödén J, Toma-Dasu I, Yu CX, Feigenberg SJ, Regine WF, Mutaf YD.  Dosimetric comparison between intra-cavitary breast brachytherapy techniques for accelerated partial breast irradiation and a novel stereotactic radiotherapy device for breast cancer:  GammaPodTM.  Phys Med Biol, 2013 Jul 7;58(13):4409-12.

Feliciano J, Feigenberg SJ, Mehta M.  Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.  Cancer J, 2013-May-Jun; 19(3):222-30

Mutaf YD, Zhang J, Yu, CX, Yi BY, Prado K, D’Souza WD, Regine WF, Feigenberg SJ.  Dosimetric and geometric evaluation of a novel stereotactic radiotherapy device for breast cancer:  the GammaPodTM.  Med Phys, 2013 Apr; 40(4): 041722.

Lu W, Neuner G, George R, Wang Z, Sasor S, Huang X, Regine WF, Feigenberg SJ, D’Souza WD.  Audio-visual biofeedback does not improve the reliability of target delineation using maximum intensity projection in 4-dimensional computed tomography radiation therapy planning.  Int J Radiat Oncol Biol Phys, 2014 Jan 1;88(1):229-35.